Research publications from the PsoProtect study group.

Publications

1. Factors associated with adverse COVID-19 outcomes – insights from a global registry-based study. J Allergy Clin Immunology; https://www.jacionline.org/article/S0091-6749(20)31413-5/fulltext
2. Risk mitigating behaviours in people with inflammatory skin and joint disease during the COVID-19 pandemic differ by treatment type: a cross-sectional patient survey. Br J Dermatol; https://onlinelibrary.wiley.com/doi/10.1111/bjd.19755
3. Describing the burden of the COVID-19 pandemic in people with psoriasis: findings from a global cross-sectional study. J Eur Acad Dermatol Venereol; https://onlinelibrary.wiley.com/doi/10.1111/jdv.17450
4. Association Between Tumor Necrosis Factor Inhibitors and the Risk of Hospitalization or Death Among Patients With Immune-Mediated Inflammatory Disease and COVID-19. JAMA Network Open; https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2785080
5. Global reporting of cases of COVID-19 in psoriasis and atopic dermatitis: an opportunity to inform care during a pandemic. Br J Dermatol; https://onlinelibrary.wiley.com/doi/10.1111/bjd.19161
6. International collaboration and rapid harmonization across dermatologic COVID-19 registries. J Am Acad Dermatol; https://doi.org/10.1016/j.jaad.2020.06.050
7. Learning from disease registries during a pandemic: Moving toward an international federation of patient registries. Clinics in Dermatology; https://www.sciencedirect.com/science/article/pii/S0738081X21000225?dgcid=author
8. Dermatology COVID-19 Registries: Updates and Future Directions. Dermatol Clin; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8165090/

Infographics